Trials / Terminated
TerminatedNCT03868540
A Study in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Oral Doses of BI 1291583 qd Versus Placebo in Healthy Male and Female Subjects for 4 Weeks (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1291583 in healthy male and female subjects following oral administration of multiple rising doses over 4 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 1291583 | tablet |
| DRUG | Placebo | tablet |
Timeline
- Start date
- 2019-03-28
- Primary completion
- 2019-11-25
- Completion
- 2019-11-25
- First posted
- 2019-03-11
- Last updated
- 2025-08-13
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03868540. Inclusion in this directory is not an endorsement.